(a) what is the specific exclusion criteria which is fulfilledi by Isoxuprine Hcl., Polymixin-B Sulphate, Flucort, Phenformin, Durabolin, Avapyrazone Pancretin and Glipizide;

(b) whether it is a fact that these drugs have been wrongly excluded from price control by Kelkar Committee as nothing is based on factual details;

(c) whether it is also a fact that as per DPCO 1987s the manufacturers have to provide sales turn-over of price decontrolled drugs formulations;

(d) if so, the details of prolormas under which sales turn-over is to be provided; and

(e) what are the details of sales turnover of the above drugs as well as of the two major selling brands of formulations of each drug during 1986 and 1987 along with their price before DPCO, 1987 and at present?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The Kelkar Committee adopted following five criterias for excluding drugs from price control:—

(i) Exclude those drugs which are not produced in India, provided that the consumption is not. significant either now or ie the near future.

(ii) To exclude those drugs the turn over of which has been less than rupees fifty lakhs in 1986.'

(iii) To exclude all new drags for which Process Of manufacture were developed indigenously from the price control list at least for the first five years.

(iv) To exclude those life-saving drugs and pharmaceutical products whose availability is far more important than the price. As the nature of demand is such that it is required less frequently but its non-availability is fatal. The [1] notable examples of such categories are sera and vaccines.

(v) Exclude those pharmaceutical products of drugs where the domestic production structure is so competitive that there is little possibility that the ctmsumer will be over-charged compared to ihe cost of production.

(c) and (b) The manufacturers are required to furnish information in Form-4 and 6 as specified under DPCO, '1987.

(e) Sales turn-over oj individual formulation is not monitored.

Prices of Flucort range of formulations

3289. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to state:

(a) what was the price Of Flucort range of formulations fixed under DPCO, 1979 and what was the price being charged by the Company;

(b) whether it is a fact that the comp-pany overcharged the prices and also imported the bulk drug at a price much lower than the price on which formulations were based;

(c) whether they were issued auy ,show-cause notice for over-charging the prices and Ifor the rtecovery under the Drug prices Equalisation Account and if so, when they were issued with such notices; and

(d) what i? the present position in this regard?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) As per the provisions of DPCO, 1987 Flucort range of formulations are price decontrolled and the concerned manufacturer is frea to revise the prices.

(b) No such instance has come to tLe notice of the Government.

(c) and (d) Do not arise in view of reply to part (b) above.

Prices of Chloramphenicol formulation

3290. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUS TRY be pleased to state:

(a) what were the prices of Chloramphenicol formulations which Parke Davi' was charging at the time of writ and what were the notified pricf